Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “omid”

33 pharma patents match "omid" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 33
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 33 pharmaceutical patents matching "omid" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

33 results for “omid” · 30,257 patents in full index Clear search

  1. US 12364683

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  2. US 12138247

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  3. US 12109196

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  4. US 12090140

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  5. US 11998528

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  6. US 11998529

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  7. US 11931340

    Use of sublingual dexmedetomidine for the treatment of agitation

    BioXcel Therapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  8. US 11890272

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  9. US 11839604

    Use of sublingual dexmedetomidine for the treatment of agitation

    BioXcel Therapeutics, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  10. US 11806429

    Film formulations containing dexmedetomidine and methods of producing them

    BioXcel Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  11. US 11806334

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  12. US 11786508

    Use of sublingual dexmedetomidine for the treatment of agitation

    BioXcel Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  13. US 11559484

    Film formulations containing dexmedetomidine and methods of producing them

    BioXcel Therapeutics, Inc. · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted
  14. US 11517524

    Film formulations containing dexmedetomidine and methods of producing them

    BioXcel Therapeutics, Inc. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  15. US 11497711

    Film formulations containing dexmedetomidine and methods of producing them

    BioXcel Therapeutics, Inc. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  16. US 11478422

    Film formulations containing dexmedetomidine and methods of producing them

    BioXcel Therapeutics, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  17. US 11253591

    Combination of lenalidomide and polypeptide construct, and uses thereof

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  18. US 10836721

    Thalidomide analogs and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted
  19. US 10792246

    Film formulations containing dexmedetomidine and methods of producing them

    BioXcel Therapeutics, Inc. · Granted Oct 6, 2020 · Expires Oct 1, 2040

    granted
  20. US 10730835

    Thalidomide analogs and methods of use

    The United States of America, as represented by the Secretary, Health and Human Services · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted
  21. US 10342869

    Compositions comprising anti-CD38 antibodies and lenalidomide

    The Regents of the University of California · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted
  22. US 10232041

    Combination of lenalidomide and polypeptide construct, and uses thereof

    TEVA PHARMACEUTICALS PTY LTD · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted
  23. US 9814706

    Hydrobromide salt of pridopidine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Nov 14, 2017 · Expires Nov 9, 2037

    granted
  24. US 9636334

    Combination of lenalidomide and polypeptide construct, and uses thereof

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted May 2, 2017 · Expires Apr 27, 2037

    granted